港股異動丨醫療器械股受捧 春立愛康創新高
格隆匯4月22日丨醫療器械股受追捧,春立醫療(1858.HK)一度高見50港元創上市新高,現報48港元,仍升7.62%。去年獲高瓴資本增持的愛康醫療(1789.HK),股價同樣創新高,高見23.6港元,現報23.5港元,漲5.62%。另外,微創醫療(0853.HK)早前宣佈,旗下微創心通亦獲得高瓴資本融資,微創醫療現大升11.7%,報19.1港元。愛康醫療與春立醫療都屬於骨科植入物企業,微創醫療產品也涵蓋骨科植入物,我國骨科植入類市場銷售規模由2014年的139億元增長至2017年的225億元,受集中採購、國產"進口替代"等因素影響,略有放緩但依然穩健發展,增速維持在10%以上。今年以來中央文件頻頻提到,要加快補齊我國高端醫療裝備短板,因此高端醫療設備的國產化進程將加快,醫療器械板塊將顯著受益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.